miR-410-3p suppresses breast cancer progression by targeting Snail

Abstract

miR-410-3p acts as an oncogene or tumor-suppressor gene in various types of cancer. However, its role in breast cancer remains unknown. In the present study, expression of miR-410-3p in 30 breast cancer and paired adjacent normal tissues was detected by RT-qPCR. The expression of miR-410-3p was downregulated in 76.7% of the breast cancer samples. To further validate the expression of miR-410-3p in breast cancer, we analyzed miR-410-3p expression profiling data set from The Cancer Genome Atlas (TCGA) including 683 breast cancer and 87 normal breast tissues. We observed that the expression of miR-410-3p was downregulated in breast cancer tissues. Next, we investigated the influence of miR-410-3p on cell proliferation by transiently transfecting the miR-410-3p mimic or inhibitor, as well as their corresponding controls in the MDA-MB-231 and MCF7 cell lines. miR-410-3p overexpression reduced cell growth, colony formation and the number of EdU-positive cells in the MDA-MB-231 cells. In contrast, inhibition of miR-410-3p in the MCF7 cells resulted in a higher proliferation rate as assessed by MTT assay, plate colony formation and EdU assays. Furthermore, miR-410-3p inhibited epithelial-mesenchymal transition. In addition, Snail was found to be a direct target of miR-410-3p based on a luciferase assay. Overexpression of Snail was able to rescue the effect of miR-410-3p in breast cancer cells. Moreover, miR‑410-3p was inversely expressed with Snail in breast cancer samples. Our data provide new knowledge regarding the role of miR-410-3p in breast cancer progression.

<p>Decreased expression of miR-410-3p correlates with poor prognosis and tumorigenesis in human glioma</p>

“…[14][15][16] Recent studies have identified miR-410-3p, a novel cancer-related miRNA, as a tumor suppressor in human breast cancer and pancreatic ductal adenocarcinoma. 17,18 Nonetheless, the biological role of miR-410-3p in glioma is still poorly understood.…”

Deregulated MicroRNAs in Cancer-Associated Fibroblasts from Front Tumor Tissues of Lung Adenocarcinoma as Potential Predictors of Tumor Promotion

“…Additional analysis showed 12 upregulated and five downregulated miR-NAs in F-CAFs compared with In-CAFs (Table 1). Among the miRNAs identified as downregulation in this study, miR-145-3p and miR-505-3p (downregulated in F-CAFs vs. NFs), miR-181c (downregulated in In-CAFs vs. NFs) and miR-410-3p and miR-485-5p (downregulated in F-CAFs vs. In-CAFs) have previously been shown to function as tumor suppressor genes and are downregulated in various tumor tissues (Yamamoto et al 2011;Guo et al 2015a;Guo et al 2015b;He et al 2016;Matsushita et al 2016;Zhang et al 2016).…”

Interplay among SNAIL Transcription Factor, MicroRNAs, Long Non-Coding RNAs, and Circular RNAs in the Regulation of Tumor Growth and Metastasis

“…In rhabdomyosarcoma, miR-410-3p inhibits tumor growth and progression by inhibition of the expression of SNAIL, SLUG, N-cadherin, and Bcl-2 [112]. However, miR-410-3p was shown previously in different tumor types to directly target SNAIL [87].…”

“…SNAIL was found to be a target of multiple miRNAs in different tumor types. SNAIL was targeted in breast cancer by miR-125b [85], miR-203 [86], miR-410-3p [87], and miR-182 [88]; in gastric cancer by miR-491-5p [89] and miR-204 [90]; in lung cancer by miR-199a [91] and miR-940 [92]; in papillary thyroid carcinoma by miR-199a [93]; in ovarian cancer by miR-137 [72] and miR-363 [94]; in hepatocellular carcinoma by miR-122 [95] and miR-502-5p [96]; in prostate cancer by miR-486-5p [97]; and in renal cancer by miR-211-5p [98]. What is more, besides tumorigenesis, SNAIL is also regulated in different processes by miRNAs.…”

“…laryngeal squamous cell carcinoma [75] melanoma [76] esophageal squamous cell carcinoma [77] gastric cancer [78] hepatocellular carcinoma [79] pancreatic ductal adenocarcinoma [80] miR-182 breast cancer [88] miR-199a lung cancer [91] papillary thyroid carcinoma [93] miR-203 breast cancer [86] miR-204 gastric cancer [90] miR-211-5p renal cancer [98] miR-363 ovarian cancer [94] miR-410-3p breast cancer [87] miR-486-5p prostate cancer [97] miR-491-5p gastric cancer [89] miR-502-5p hepatocellular carcinoma [96] miR-940 lung cancer [92]…”